HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
SNTI
Senti Biosciences, Inc.
There isn't enough reported data to score SNTI yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
SNTI Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
SNTI's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
SNTI PE Valuation
SNTI has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
SNTI Forward outlook
There aren't enough analyst estimates for SNTI to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
SNTI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$27.34 | -$6.04 |
| Q2 2024 | -$24.43 | -$2.73 |
| Q1 2024 | -$26.18 | -$0.08 |
SNTI has the edge over HIMS in the latest year-over-year earnings comparison.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over SNTI on profitability, with a higher operating margin.
SNTI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2023 | $338K | -81% |
| Q2 2023 | $937K | -31% |
| Q4 2022 | $59K | -93% |
| Q4 2021 | $793K | +39550% |
SNTI's revenue has slid since its 2022 peak: $17,000 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -85229% | N/A |
| Q1 2026 | -28850% | N/A |
| Q3 2023 | -12981% | -12014 points |
| Q2 2023 | -2096% | -492 points |
| Q1 2023 | -1542% | N/A |
| Q4 2022 | -33925% | -32553 points |
| Q3 2022 | -967% | N/A |
| Q2 2022 | -1603% | N/A |
SNTI's operating margin was −85229% last quarter, down 83687 points from the same quarter a year ago, near the bottom of its range since 2020.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
SNTI has the stronger cash trend. Its trailing FCF is up 34% versus its history, compared with HIMS at down 84%.
SNTI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$7.5M | +$6.6M |
| Q4 2025 | -$6.9M | +$6.6M |
| Q3 2025 | -$9.4M | -$1.6M |
| Q2 2025 | -$13.3M | -$4.9M |
| Q1 2025 | -$14.1M | -$2.4M |
| Q4 2024 | -$13.5M | -$6.5M |
| Q3 2024 | -$7.9M | +$9.4M |
| Q2 2024 | -$8.3M | +$9M |
SNTI has burned cash in almost every quarter: −$37M over the past year, against −$44M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over SNTI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
SNTI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +173K shares |
| 1 year | +211% | +21.1M shares |
| 3 years | +607% | +26.7M shares |
SNTI has 31M diluted shares, up 211% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
SNTI Net Leverage
SNTI's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
SNTI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.7 | Oversold |
| Stochastic | 3.2 | Oversold |
SNTI's weekly RSI is 25 (oversold) and its Stochastic is 3 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
SNTI PE vs Healthcare Sector
SNTI has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
SNTI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.23 | 35% below |
| 20 week MA | $0.38 | 61% below |
| 50 week MA | $0.77 | 81% below |
| 100 week MA | $1.79 | 92% below |
| 200 week MA | $3.87 | 96% below |
SNTI is in a downtrend: it's below all five of its weekly moving averages, and 96% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over SNTI on returns for 2026, with the stronger performance.
SNTI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $100.0 | $98.5 | -1.5% |
| 2022 | $98.5 | $13.4 | -86% |
| 2023 | $13.4 | $6.60 | -51% |
| 2024 | $6.60 | $3.92 | -41% |
| 2025 | $3.92 | $1.06 | -73% |
| 2026 YTD | $1.06 | $0.15 | -86% |
SNTI has finished every year since 2021 lower, and it's down 86% so far in 2026.